You are using a version of the website built for webcrawlers and people whose devices cannot use javascript.
Some functionality will not be available.
Warning: This page is an archive.
General administrative information and links are not current and should not be used.
Contents (2008 - 392)
Poisons and Therapeutic Goods Regulation 2008
Current version for 1 July 2017 to date (accessed 23 November 2017 at 22:17)
Part 3 Division 3 Clause 35
35   Form of prescription
(1)  A prescription for a restricted substance must include the following details:
(a)  the date on which it is issued,
(b)  if the treatment is for:
(i)  a patient—the name and address of the patient, or
(ii)  an animal—the species of animal and the name and address of the animal’s owner, or
(iii)  a patient’s partner and the prescription is for azithromycin for the treatment of chlamydia—the name and email address or mobile phone number of the partner,
(c)  the name, strength (if not readily apparent) and quantity of the substance to be supplied,
(c1)  the route of administration (if not readily apparent) of the substance to be supplied,
(d)  adequate directions for use,
(e)  the maximum number of times the substance may be supplied on the prescription,
(f)  in the case of a prescription for a special restricted substance, the intervals at which the substance may be supplied on the prescription,
(g)  if the prescription is issued at a hospital, the name and designation of the person by whom it is issued and the name, address and telephone number of the hospital,
(h)  if the prescription is issued elsewhere than at a hospital, the name and designation of the person by whom it is issued and the address and telephone number of the premises at which it is issued.
(1A)  As an alternative to complying with subclause (1), a medication chart prescription authorising the supply of a substance that is not a special restricted substance or a substance listed in clause 37 must include the following details:
(a)  the date on which it is issued,
(b)  the name and address of the patient,
(c)  the name and form (if not readily apparent) of the substance to be supplied,
(d)  the strength (if not readily apparent) of the substance to be supplied,
(e)  the route of administration (if not readily apparent) of the substance to be supplied,
(f)  adequate directions for use,
(g)  the frequency or times at which the substance is to be administered or used,
(h)  the period during which the substance is to be used or administered (being a period that ends on a date that is no more than 4 months from the date of first use of the relevant chart for the resident),
(i)  the name and designation of the person by whom it is issued,
(j)  the name, address and telephone number of the relevant residential care facility.
(2)  The details referred to in subclause (1A) (b) and (j) can be made out by any person.
(2A)  The details referred to in subclause (1) or (1A) (a) or (c)–(i) must be made out:
(a)  in the handwriting of the person by whom the prescription is issued, or
(b)  in such other manner as may be approved for the time being by the Director-General.
(2B)  A prescription must be signed by the person by whom it is issued (whether it complies with subclause (1) or (1A)).
(3)  The person by whom the prescription is issued must confirm any dose that could be regarded as being dangerous or unusual by underlining the part of the prescription that specifies the intended dose and by initialling the prescription in the margin.
(4)  A person who issues a prescription for a restricted substance must ensure that the prescription complies with the requirements of this clause.
(5)  The Director-General may, by order in writing, exempt any person or restricted substance, or any class of persons or restricted substances, from any or all of the requirements of this clause.
(6)  Such an exemption may be given unconditionally or subject to conditions.
(7)  In this clause:
partner of a patient includes any of the following:
(a)  the patient’s spouse,
(b)  the patient’s de facto partner,
(c)  a person with whom the patient is or was in a sexual relationship.
(8)  Subclauses (1) (b) (iii) and (7) cease to have effect on 1 January 2018.
Maximum penalty: 15 penalty units.